Caricamento...
Cardiovascular safety trials of incretin‐based drugs: What do they mean?
Incretin‐based dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists are newer choices of antidiabetic medications that are now most widely used worldwide. Preclinical study results suggest that the two drugs potentially exert benefits to prevent onsets and/or progressions...
Salvato in:
| Pubblicato in: | J Diabetes Investig |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5415478/ https://ncbi.nlm.nih.gov/pubmed/27612317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12576 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|